Managed Markets Insight & Technology Blog Even at 10% Discount, Eylea Biosimilar Pavblu Offers Lower-Cost Option

Although the FDA has approved five biosimilars of Regeneron Pharmaceuticals, Inc.’s best-selling Eylea (aflibercept), patent infringement lawsuits by the drugmaker have kept those competitors off the U.S. market — until now. Following a successfu... Read More